A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum.

ABSTRACT: This expanded access study will assess the safety and efficacy of intravenous bevacizumab (5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks) in combination with fluoropyrimidine-based chemotherapy as first line treatment in participants with metastatic cancer of the colon or rectum. The anticipated time on study treatment is 3-12 months.

DISEASE(S): Neoplasm Metastasis,Colorectal Cancer,Colonic Neoplasms

PROVIDER: 2092632 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR